Nuwellis Inc. announced the presentation of new real-world data from Lenox Hill Hospital at the 2025 American Society of Nephrology (ASN) Kidney Week. The retrospective analysis reviewed 69 cases treated with the Aquadex® ultrafiltration therapy between 2018 and 2024. The study highlighted the device's effectiveness and predictability in fluid removal for patients with conditions such as acute kidney injury and complex fluid management needs, including those on vasopressor support. Patients had an average of 6.4 liters of ultrafiltrate removed over a mean duration of 78 hours with stable hemodynamics. The study demonstrated the versatility of Aquadex across a range of critical care settings.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9598924) on December 09, 2025, and is solely responsible for the information contained therein.